In this issue:
Leukaemia selection
Single-agent ibrutinib vs. chemoimmunotherapy for untreated CLL
Ibrutinib regimens vs. chemoimmunotherapy in older untreated CLL
CITE antibody reverses adaptive immune escape in AML
MRD, conditioning intensity and age predict outcomes after allogeneic HCT for AML in first CR
NPM1-mutated AML can relapse with wildtype NPM1 and evolve with novel mutations
Lymphoma selection
Rituximab + lenalidomide in advanced untreated follicular lymphoma
CD47 blocker plus rituximab in non-Hodgkin’s lymphoma
5-year outcomes with lenalidomide + rituximab as initial MCL treatment
Intensive treatment strategies in advanced-stage Hodgkin’s lymphoma
Interim PET-based treatment of nonbulky early-stage Hodgkin’s lymphoma
Please login below to download this issue (PDF)